A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.
复制标题
DOI：
10.1111/j.1600-0447.2008.01325.x
复制
发表时间：
2009-06
影响因子：
6.7
通讯作者：
Goff DC
中科院分区：
文献类型：
--
作者：
Henderson DC;Fan X;Sharma B;Copeland PM;Borba CP;Boxill R;Freudenreich O;Cather C;Eden Evins A;Goff DC
The primary purpose of this eight week double blind, placebo-controlled trial of rosiglitazone 4 mg/day was to examine its effect on insulin sensitivity index (SI) and glucose utilization (SG) in clozapine-treated schizophrenia subjects with insulin resistance. Eighteen subjects were randomized and accessed with a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT) at the baseline and week 8 to estimate SG, and SI. Controlling for the baseline, comparing the rosiglitazone group to placebo group, there was a non-significant improvement of SG (0.016± 0.006 to 0.018± 0.008, effect size= 0.23, p= 0.05) with a trend of improvement in SI in the rosiglitazone group (4.6± 2.8 to 7.8± 6.7, effect size= 0.18, p= 0.08). There was a significant reduction in small low-density-lipoprotein cholesterol (LDL-C)- particle number (987± 443 to 694± 415, effect size= 0.30, p= 0.04). Rosiglitazone may have a role in addressing the insulin resistance and lipid abnormalities associated with clozapine.
登录
查看更多内容
影响因子：
4.8
作者：
Hennekens, CH;Hennekens, AR;Casey, DE
通讯作者：
Casey, DE
影响因子：
9.8
作者：
Goff, DC;D'Agostino, RB;Otvos, JD
通讯作者：
Otvos, JD
影响因子：
7.7
作者：
Garvey, WT;Kwon, S;Liao, YL
通讯作者：
Liao, YL
影响因子：
5
作者：
Ding, Guoliang;Qin, Qianhong;Yang, Qinglin
通讯作者：
Yang, Qinglin
影响因子：
5.8
作者：
Ghanim, Husam;Dhindsa, Sandeep;Dandona, Paresh
通讯作者：
Dandona, Paresh